- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic obstructive pulmonary disease (COPD)
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 409KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 61KB)
Tiotropium with olodaterol – November 2024
Tiotropium with Olodaterol; Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses, pack of 2; Spiolto® Respimat®
Last updated
30 May 2025
